156 related articles for article (PubMed ID: 38077371)
21. Cytomegalovirus colitis in immunocompetent patients: a clinical and endoscopic study.
Seo TH; Kim JH; Ko SY; Hong SN; Lee SY; Sung IK; Park HS; Shim CS; Han HS
Hepatogastroenterology; 2012 Oct; 59(119):2137-41. PubMed ID: 23435132
[TBL] [Abstract][Full Text] [Related]
22. Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management.
Tang L; Wang J; Lin N; Zhou Y; He W; Liu J; Ma X
Front Immunol; 2021; 12():800879. PubMed ID: 34992611
[TBL] [Abstract][Full Text] [Related]
23. Cytomegalovirus colitis followed by ischemic colitis in a non-immunocompromised adult: a case report.
Hasegawa T; Aomatsu K; Nakamura M; Aomatsu N; Aomatsu K
World J Gastroenterol; 2015 Mar; 21(12):3750-4. PubMed ID: 25834346
[TBL] [Abstract][Full Text] [Related]
24. Successful treatment of advanced pulmonary sarcomatoid carcinoma with the PD-1 inhibitor toripalimab: A case report.
Jiao Y; Liu M; Luo N; Guo H; Li J
Oral Oncol; 2021 Jan; 112():104992. PubMed ID: 32943323
[TBL] [Abstract][Full Text] [Related]
25. Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy.
Finazzi T; Rordorf T; Ikenberg K; Huber GF; Guckenberger M; Garcia Schueler HI
BMC Cancer; 2018 Apr; 18(1):395. PubMed ID: 29625593
[TBL] [Abstract][Full Text] [Related]
26. Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis.
Lankes K; Hundorfean G; Harrer T; Pommer AJ; Agaimy A; Angelovska I; Tajmir-Riahi A; Göhl J; Schuler G; Neurath MF; Hohenberger W; Heinzerling L
Oncoimmunology; 2016 Jun; 5(6):e1128611. PubMed ID: 27471608
[TBL] [Abstract][Full Text] [Related]
27. Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers.
Wang Y; Zou J; Li Y; Jiao X; Wang Y; Zhuo N; Gao M; Gong J; Li J; Zhang X; Wang X; Peng Z; Qi C; Wang Z; Li J; Li Y; Shen L; Zhang H; Lu Z
Front Immunol; 2022; 13():987568. PubMed ID: 36159840
[TBL] [Abstract][Full Text] [Related]
28. Immune Checkpoint Inhibitors for Nasopharyngeal Carcinoma in a Real-world Setting in Japan.
Manako T; Yasumatsu R; Nakano T; Matsuo M; Takeuchi T; Taura M; Tamae A; Yamauchi M; Masuda M; Taguchi K; Nakagawa T
In Vivo; 2023; 37(2):747-755. PubMed ID: 36881083
[TBL] [Abstract][Full Text] [Related]
29. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210
[TBL] [Abstract][Full Text] [Related]
30. Association between immune-related adverse events and the efficacy of PD-1 inhibitors in advanced esophageal cancer.
Qin W; Yang L; Fan B; Zou B; Duan Y; Li B; Wang L
Front Immunol; 2022; 13():931429. PubMed ID: 36248782
[TBL] [Abstract][Full Text] [Related]
31. Recurrent Cystitis Associated With 2 Programmed Death 1 Inhibitors: A Rare Case Report and Literature Review.
Fan Y; Zhao J; Mi Y; Zhang Z; Geng Y; Zhou L; Shen L; Zhang Z
J Immunother; 2023 Nov-Dec 01; 46(9):341-345. PubMed ID: 37721343
[TBL] [Abstract][Full Text] [Related]
32. Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases.
Pizuorno Machado A; Shatila M; Liu C; Wang J; Altan M; Zhang HC; Thomas A; Wang Y
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6341-6350. PubMed ID: 36752908
[TBL] [Abstract][Full Text] [Related]
33. Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?
Masterson L; Howard J; Gonzalez-Cruz J; Jackson C; Barnett C; Overton L; Liu H; Ladwa R; Simpson F; McGrath M; Wallwork B; Jones T; Ottensmeier C; Chua MLK; Perry C; Khanna R; Panizza B; Porceddu S; Lechner M
Int J Cancer; 2020 Apr; 146(8):2305-2314. PubMed ID: 31950498
[TBL] [Abstract][Full Text] [Related]
34. Is Immune Therapy Plus Chemotherapy More Effective Than Immune Therapy Alone for Unresectable Recurrent Nasopharyngeal Carcinoma?
Zhou X; Niu X; Liu P; Ou D; Zhu Y; Wang X
Front Immunol; 2021; 12():762663. PubMed ID: 34777379
[TBL] [Abstract][Full Text] [Related]
35. Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trial.
Hua Y; You R; Wang Z; Huang P; Lin M; Ouyang Y; Xie Y; Zou X; Liu Y; Duan C; Liu Y; Gu C; Liu R; Yang Q; Jiang R; Zhang M; Ding X; Chen S; Lin C; Sun R; Chen M
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34782428
[TBL] [Abstract][Full Text] [Related]
36. Everolimus-associated cytomegalovirus colitis in a patient with metastasized breast cancer: a case report.
Yang JR; Shao YC
Breast Cancer; 2020 Jul; 27(4):776-779. PubMed ID: 31773503
[TBL] [Abstract][Full Text] [Related]
37. Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials.
Wang M; Liang H; Wang W; Zhao S; Cai X; Zhao Y; Li C; Cheng B; Xiong S; Li J; He J; Liang W
Cancer; 2021 Mar; 127(5):777-786. PubMed ID: 33119182
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemotherapy as First-line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-analysis of Randomized Controlled Trials.
Sun H; Bu F; Li L; Zhang X; Xin X; Yan J; Huang T
Ann Pharmacother; 2024 Apr; 58(4):349-359. PubMed ID: 37488978
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of PD-1 inhibitors in recurrent or metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens: a systematic review and meta-analysis.
Luo J; Xiao W; Hua F; Cao Y; Wang D; Wang X
BMC Cancer; 2023 Nov; 23(1):1172. PubMed ID: 38037076
[TBL] [Abstract][Full Text] [Related]
40. Gastrointestinal Adverse Events Induced by Immune-Checkpoint Inhibitors.
Yanai S; Toya Y; Sugai T; Matsumoto T
Digestion; 2021; 102(6):965-973. PubMed ID: 34515105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
